–Collaboration Focuses on Innovative NAD+ Precursors and Enhanced Wellness Solutions–
SHANGHAI, China – Sept.12.2024 – EffePharm is honored to announce its partnership with Dr. Rubén Zapata-Pérez from the Catholic University of Murcia (UCAM). This collaboration marks a significant milestone in the exploration of novel NAD+ precursors, highlighting the immense health potential of NMNH (reduced nicotinamide mononucleotide).
Dr. Zapata, the first author of the groundbreaking research paper, “Reduced Nicotinamide Mononucleotide is a New and Potent NAD+ Precursor in Mammalian Cells and Mice,” discovered that NMNH increases NAD+ levels up to tenfold. His research emphasizes the transformative health potential of NMNH, which surpasses traditional NAD+ boosters like NMN and NR.
“NMNH has set a new standard in NAD+ boosting, largely overpassing the effects of the classical boosters like NMN and NR,” stated Dr. Zapata-Pérez. “Until now, the availability of pure NMNH posed a significant challenge, but EffePharm has solved this issue by providing high-quality NMNH in bulk. This breakthrough opens up new opportunities to test the potential therapeutic effects of this compound in our in vitro and in vivo models of disease.”
About UthPeak™ NMNH
EffePharm’s UthPeak™ NMNH is believed to be the first brand to achieve self-affirmed GRAS status as a next-generation NAD+ precursor. Extensive toxicology and efficacy tests conducted in animal models reveal multiple potential health benefits, including anti-aging effects, improved sleep quality, enhanced brain function, and cardiovascular health support. EffePharm is also conducting human clinical trials to validate UthPeak™ NMNH's safety, with results expected by the end of 2024.
Innovating NAD+ Research
Dr. Zapata's research group specializes in developing novel therapies using both classical and innovative NAD+ enhancers, combined with other bioactive compounds, for in vitro and in vivo models of inherited or acquired mitochondrial diseases. Through this strategic partnership, EffePharm aims to reinforce its leadership in NAD+ research and deepen its commitment to providing clients with scientifically backed solutions for enhanced wellness and anti-aging benefits.
For media inquiries or further information, please contact EffePharm Marketing marketing@effepharm.com.
About EffePharm:
Founded in 2017, EffePharm is a biotechnology company specializing in providing advanced wellness solutions to its global users. EffePharm is founded on the belief that everyone should have equal access to health and nutrition. EffePharm advocates for innovative bioscience applications, increased accessibility of nutrition, and improved quality of life. Committed to delivering efficacy-verified products to the market, EffePharm has established a portfolio of over 600 business partners worldwide, benefiting millions of consumers to thrive throughout their health and nutrition journeys.
About Catholic University of Murcia (UCAM): Leading Health Innovation and Research
UCAM stands out as a leader in research and innovation, particularly in the health sector, with advanced facilities in molecular biology, microbiology, bioinformatics, and clinical analysis. Ranked among the top 60 universities worldwide for teaching and research, UCAM combines academic excellence with cutting-edge technology. Its UCAM HiTech center, a startup accelerator, fosters entrepreneurship and innovation in health, food, and sports, connecting scientific projects with investors. With over 450 collaboration agreements and world-class research infrastructure, UCAM continues to drive impactful advancements in health sciences.
Comments